Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03978039

National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group

The BCB SARCOMES database is a clinical and biological national database dedicated to sarcoma that contains 3 main databases with specific aims: the first is the pathology database (French expert network dedicated to the management of bone sarcomas [RESOS] / French expert network dedicated to the pathology of sarcomas [RREPS]), dedicated to systematic review of mesenchymal tumor diagnostics nationwide; the second is clinical (RESOS / French expert clinical network for sarcomas [NETSARC]), collecting multidisciplinary tumor boards (MDTB) data of patients nationwide, and the third (CONTICABASE / BONE / GIST) is dedicated to collecting patients longitudinal/follow up data, with a focus on treatments of every events, and a catalogue of associated samples.

Primary objectives of BCB-SARCOMES are the following: description of the patterns of care and treatment outcomes, assessment of the prognostic factors of patients' outcomes.

With the financial support of the French National Cancer Institute [Institut National du cancer [INCa]).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Sarcoma Neoplasms Neoplasms by Histologic Type Neoplasms, Connective and Soft Tissue

Sex eligibility

All sexes

Study type

Observational

Primary location

Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of sarcoma
  • Diagnosis in a French Comprehensive Cancer Center
  • Any age

Treatment and study plan

Chemotherapy

Drug

treatment as per standard of care

Immunotherapeutic Agent

Drug

treatment as per standard of care

target treatment

Drug

treatment as per standard of care

Surgery

Procedure

treatment as per standard of care

Radiotherapy

Radiation

treatment as per standard of care

Primary outcomes

  1. Time to next treatment (TNT)

    Time frame: 2 years

    Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.

  2. Time to next treatment (TNT)

    Time frame: 5 years

    Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.

  3. Overall survival (OS)

    Time frame: 2 years

    Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact.

  4. Overall survival (OS)

    Time frame: 5 years

    Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact.

Study contacts

Contact information is provided by the study sponsor or research team.

Maud Toulmonde, MD

CONTACT

[email protected]

0556333333

Simone Mathoulin-Pélissier, MD/PhD

CONTACT

[email protected]

05563333

Sponsors and collaborators

Lead sponsor

Institut Bergonié

Other

Collaborators

  • French Sarcoma Group

Registry information

Official study title

The "BCB-sarcomes" Database: the Database of the French Sarcoma Group Dedicated to the Collection of Clinical and Biological Data for All Sarcomas

Acronym: BCB-Sarcomes

Important dates

Study start
2010
Primary completion
2030
Study completion
2035
First posted
Jun 6, 2019
Registry last updated
Sep 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.